Security of supply and politics - a conflict? / Third national Swiss Medtech MDR&IVDR Conference
plus
Actualités sur Medicale
Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients
- Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver - Bempedoic acid significantly reduced LDL-Cholesterol (LDL-C) vs placebo at week 12 (primary endpoint, absolute reduction -36mg/dL, -21,4%) - Over 24-weeks, bempedoic acid was ...
plusFDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease - MAVENCLAD demonstrated significant efficacy across key measures of disease activity ...
plusMicreos Raises EUR30 Million for Endolysin Technology Set to Replace Antibiotics / Funding for clinical development program XZ.700 and Gladskin Eczema USA launch
THE HAGUE, Netherlands (ots) - Dutch biotechnology company Micreos announced it has secured EUR30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its ...
plusMundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer
FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future treatment option in this area of significant ...
plusMountain Rescue Study Launches to Investigate Use of Penthrox® (Methoxyflurane) for Trauma-related Pain in Hostile Environments
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY - Study will enrol 200 adult patients with limb trauma who are rescued by helicopter - Efficacy, tolerability and practicality of use of the inhaled analgesic in hostile mountain environments to be investigated Cambridge, England (ots/PRNewswire) - The Mundipharma network ...
plusMallinckrodt Announces 2019 Investigator Award for Pioneering Efforts in ECP Immunomodulation
EUR50,000 award goes to Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust Staines-Upon-Thames, England (ots/PRNewswire) - Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation ...
plusMAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
plusMAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
plusOral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO
New Orleans (ots/PRNewswire) - Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for oral semaglutide 3 mg for HbA1c reductions at 26 weeks was not confirmed. Presented today at the Endocrine Society Annual Meeting in ...
plusGenePOC obtains FDA clearance for its GenePOC(TM) Strep A test in the US
Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene(TM) device. About Group A Streptococcus (GAS) infection GAS is the most common bacterial etiology of pharyngitis accounting for 15 to 30% cases in children and 5 to 20% in adults[1]. In the ...
plusPrimex Pharmaceuticals and Nordic Group Sign a Strategic Partnership to Commercialise OZALIN® in France
Paris and Zug, Switzerland (ots/PRNewswire) - Nordic Group, a pharmaceutical company focusing on the development and commercialisation of hospital and orphan products, and Primex Pharmaceuticals AG, an innovative global Anaesthesia pharmaceutical company, announced a strategic agreement today to launch OZALIN® in ...
plusUK Schools Rank Last in Providing Oral Health Education, FDI Survey of 13 Countries Says
plusMerck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...
plusData from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-daily LIXIANA® Undergoing Diagnostic or Therapeutic Procedures
Munich (ots/PRNewswire) - - In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA® (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented - EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural ...
plusCLEAR Wisdom Demonstrated First-in-class, Oral, Once-daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
- Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 CLEAR Wisdom at the American College of Cardiology (ACC) 2019 Scientific Sessions - Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated and Adverse Event Profile was Similar to that of Placebo[1] - Bempedoic Acid is an ...
plusNyxoah Receives European CE Mark Approval for the Genio® System, a Disruptive Neurostimulation Solution for Obstructive Sleep Apnea Therapy
Mont-Saint-Guibert, Belgium (ots/PRNewswire) - Nyxoah S.A., a healthtech company focusing on the development of innovative solutions and services for sleep related disorders, today announced that the company has received CE Mark approval for the Genio® system in Europe. The Genio® system is the world's first and ...
plusDaiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA® (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation
Munich (ots/PRNewswire) - - ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice - Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm ...
plusMerck Announces Collaboration With Iktos for Generative Artificial Intelligence (AI) Technology
Darmstadt, Germany (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Collaboration agreement enables Merck access to Iktos AI technology across three drug discovery projects - Generative modelling AI technology enables rapid and cost-effective design of novel drugs - Agreement is part of Merck's R&D strategy to advance drug discovery with strategic ...
plusOxford Nanopore Launches Flongle for Rapid, Smaller DNA/RNA Sequencing Tests in Any Environment
Oxford, England (ots/PRNewswire) - Oxford Nanopore has today made Flongle starter packs available to purchase https://store.nanoporetech.com/flongle.html, after initial testing in an early-access programme. Flongle introduces a new paradigm of smaller, on-demand DNA or RNA sequencing tests, with the potential to ...
plus- 2
FDI: Endodontics white paper calls for treatment to consider impact on patient health and well-being
plus ArisGlobal Launches Enterprise-Level Document Management Platform
LifeSphere® EasyDocs enables the life sciences industry to eliminate multiple siloed applications and reduce integration complexities while unifying document management Miami (ots/PRNewswire) - ArisGlobal, a leading provider of life sciences software that automates core drug development functions for over 200 global life sciences companies, today announced the ...
plusElsevier Launches Assessment Capabilities on Its All-new ClinicalKey Student Platform
London (ots/PRNewswire) - ClinicalKey Student equips medical faculty and students with the resources they need to enhance the teaching and learning experience Elsevier (https://www.elsevier.com/), the information analytics business specializing in science and health, announced today the launch of new assessment capabilities available on its refreshed and rebranded ...
plusBlueBee Receives Health Data Hosting (HDS) Certification
Rijswijk, Netherlands (ots/PRNewswire) - BlueBee, a global bioinformatics solutions provider, has been awarded the HDS:2018 certification for its Information Security Management System (ISMS). The Hébergeurs de Données de Santé or Health Data Hosting (HDS) accreditation is required for entities hosting personal health data governed by French laws. The British Standards Institution (BSI) conducted the audit and ...
plusThe expansion stage seeks to establish the overall response rate (ORR), duration of response (DR) and safety of five patient cohorts
Basel, Switzerland (ots/PRNewswire) - Mundipharma EDO GmbH, part of the Mundipharma global network of independent associated companies, today announced that the first patient has been enrolled in the expansion stage of a Phase I/II clinical trial of tinostamustine in patients with relapsed/refractory (R/R) ...
plusOzempic® Superior in Lowering Blood Sugar and Weight Vs Placebo, Both in Combination with SGLT-2 Inhibitors
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the efficacy and safety of Ozempic® (semaglutide) 1.0 mg when added to SGLT-2 inhibitor (SGLT-2i) ...
plusImportant New Trial With Oral FERACCRU® Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4]
Amsterdam (ots/PRNewswire) - - FERACCRU® (Ferric Maltol) met primary endpoint against Ferinject® (IV Ferric Carboxymaltose (FCM)) and shows clear benefits to Iron Deficiency Anaemia (IDA) patients with inactive Inflammatory Bowel Disease (IBD)4 - FERACCRU® delivered a haemoglobin (Hb) response rate at 12 weeks ...
plusMED-EL Study Shows That a Quarter of Adults Have Never Had Their Hearing Checked
London (ots/PRNewswire) - BRITS are the worst in the world for having their hearing tested, a major study reveals. Almost half (46%) have NEVER had their ears checked, compared to just 11% in Russia and 19% in the US. In an international study of 11,000 adults across the globe, the UK has ranked the worst at having their hearing checked. The research, commissioned by ...
plusHitachi Medical Systems Europe Holding AG
2Hitachi Medical Systems Europe presents the next generations in Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) at the European Society of Radiology, February 28, 2019
plusHitachi Medical Systems Europe Holding AG
3Good health runs in families / Hitachi Medical Systems Europe welcomes five new family members to the diagnostic ultrasound series at the European Society of Radiology
plus
Précédent16171819202122232425Suivant